Published Date: 30-Nov-2022
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report, published by KBV research, The Global Tendonitis Treatment Market size is expected to reach $252.3 billion by 2028, rising at a market growth of 3.7% CAGR during the forecast period.
The Therapy segment acquired maximum revenue share in the Global Tendonitis Treatment Market by Type in 2021 thereby, achieving a market value of $168.2 billion by 2028. The preference of tendonitis patients for non-invasive therapies is seen to be a factor in the segment's rise. Because it is the first line of treatment for tendonitis and helps patients with chronic tendon problems, the physical therapy sub-segment held the biggest market share in the therapy category.
The Jumper’s Knee segment is showcasing a CAGR of 3.9% during (2022 - 2028). Overusing the knee joint, such as by repeatedly jumping on hard surfaces, can result in a jumper's knee. The best course of action for the jumper's knee is to cease all aggravating activities until the condition has healed. Nonsteroidal anti-inflammatory medications and heat & cold therapy are examples of other treatments.
The North America market dominated the Global Tendonitis Treatment Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $102.9 billion by 2028.The Europe market is exhibiting a CAGR of 3.4% during (2022 - 2028). Additionally, The Asia Pacific market would showcase a CAGR of 4.4% during (2022 - 2028).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Merck & Co., Inc., Bayer AG, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Abbott Laboratories, Pfizer, Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd., and Almatica Pharma, Inc.
Unique Offerings from KBV Research